BUSINESS

• Otsuka Pharma Sales Rise 7.1% in 2025, Driven by Rexulti
  February 16, 2026

• Gilead Japan Files Trodelvy for 1st-Line TNBC in PD-1/PD-L1-Ineligible Patients
  February 16, 2026

• FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
  February 13, 2026

• Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
  February 13, 2026

• Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
  February 13, 2026

• Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
  February 13, 2026

• Nxera Licenses GPCR Program to European VC-Backed Startup
  February 13, 2026

• Alfresa Launches Neffy Nasal Spray for Anaphylaxis in Japan
  February 13, 2026

• Teijin Seeks Japan Nod for Ascendis’s GHD Drug
  February 13, 2026

• Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
  February 12, 2026

• Takeda’s Narcolepsy Drug Accepted for US FDA Review
  February 12, 2026

• FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
  February 12, 2026

• Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
  February 12, 2026

• MFN Policy Could Affect Business Outside US: Kyowa Kirin CEO
  February 12, 2026

• Kyowa Kirin Aims to Raise Core Margin to 30% on Late-Stage Launches
  February 12, 2026

• Chugai Exercises Option to Develop Multi-Payload ADCs with Araris
  February 12, 2026

• Astellas Settles US Myrbetriq Patent Row with Lupin, Zydus
  February 12, 2026

• Rohto Invests More in Osaka University Spinout Raymei
  February 12, 2026

• Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
  February 12, 2026

• J&J Files Tecvayli/Darzquro Combo for MM in Japan
  February 12, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »